Premium
Optimising low‐dose methotrexate for rheumatoid arthritis—A review
Author(s) -
Lucas Catherine J.,
Dimmitt Simon B.,
Martin Jennifer H.
Publication year - 2019
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14057
Subject(s) - rheumatoid arthritis , methotrexate , medicine , population , pharmacology , arthritis , environmental health
Methotrexate at low doses (5–25 mg/week) is first‐line therapy for rheumatoid arthritis. However, there is inter‐ and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose–response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.